

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊

中国新药杂志
二〇二二年
第三十一卷
第二十三期
第2289-2392页
半月刊

CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734
CN 11-2850/R
CODEN ZXZHA6

中國新葯雜誌



23
2022
Vol.31 | No.23

乌帕替尼在风湿免疫领域临床研究进展
IgG4相关性疾病药物治疗进展
基于病证结合的类风湿关节炎中成药治疗思考
系统性红斑狼疮的靶向治疗药物研究进展
生物制剂时代幼年特发性关节炎的治疗策略
艾拉莫德治疗痛风的网络药理学机制研究
艾拉莫德对临床前类风湿关节炎的潜在治疗价值

本期得到江苏先声药业有限公司的大力支持

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



•风湿免疫疾病药物治疗专题•

- 2289 乌帕替尼在风湿免疫领域临床研究进展·····王文社, 苏茵, 贾园
- 2296 IgG4相关性疾病药物治疗进展·····郑岷敏, 聂玉雪, 张文
- 2304 基于病证结合的类风湿关节炎中成药治疗思考·····宋梦歌, 姜泉, 巩勋, 等
- 2310 系统性红斑狼疮的靶向治疗药物研究进展·····陈晓梅, 吴雪, 罗采南, 等
- 2318 生物制剂时代幼年特发性关节炎的治疗策略·····李彩凤, 史昕炜, 邓江红
- 2323 艾拉莫德治疗痛风的网络药理学机制研究·····曾惠琼, 陈帅, 卢小平, 等
- 2329 艾拉莫德治疗原发性干燥综合征的临床应用及作用机制·····邹瑶, 肖伟, 李丽华, 等
- 2333 基于OPG/RANKL/RANK信号通路探讨清热利湿活血法对活动期类风湿关节炎骨代谢的影响及临床疗效观察
·····张迪, 樊冰, 刘英, 等
- 2338 艾拉莫德对临床前类风湿关节炎的潜在治疗价值·····刘群, 邵慧君, 李晓玲, 等
- 2345 阿巴西普治疗多种生物制剂治疗失败的类风湿关节炎1例·····吴春叶, 阚燕, 孔纯玉

•新药述评与论坛•

- 2350 真实世界数据在非处方药领域的应用与治理·····章颖, 王闻雅

•新药注册与审评技术•

- 2355 国家药品监督管理局、美国FDA与ICH基于生物药剂学分类系统的生物等效性豁免指导原则的比较·····王功富, 汤佳, 白玉, 等
- 2361 阿司匹林肠溶片的生物等效性试验设计要点及审评考虑·····王静, 李丽, 陈思, 等
- 2365 通用技术文档格式申报资料中非临床研究资料的撰写·····周恒, 戴学栋, 翟云, 等

•综述•

- 2369 眼脉络膜新生血管动物模型及其与临床发病机制相关性研究·····谢金华, 宋硕, 熊亚妮, 等
- 2377 放射性核素偶联药物的研究进展·····陶巧玉, 许波华, 李嫚琪, 等

•药物安全与合理应用•

- 2385 33例信迪利单抗不良反应的文献分析·····吴玉佩, 尹岳松, 张丽娜, 等

- 2289 Research progress of upadacitinib in the treatment of rheumatic immune diseases WANG Wen-she , SU Yin , JIA Yuan
- 2296 Advances in drug therapy for IgG4-related diseases ZHENG Min-min , NIE Yu-xue , ZHANG Wen
- 2304 Considerations on the treatment of rheumatoid arthritis with Chinese patent medicine based on the combination of disease and syndrome SONG Meng-ge , JIANG Quan , GONG Xun , *et al*
- 2310 Advances in targeted therapeutic agents for systemic lupus erythematosus CHEN Xiao-mei , WU Xue , LUO Cai-nan , *et al*
- 2318 Treatment strategies of juvenile idiopathic arthritis in biologics era LI Cai-feng , SHI Xin-wei , DENG Jiang-hong
- 2323 The network pharmacological mechanism of iguratimod in the treatment of gout ZENG Hui-qiong , CHEN Shuai , LU Xiao-ping , *et al*
- 2329 Clinical application and mechanism of iguratimod in the treatment of primary Sjögren's syndrome ZOU Yao , XIAO Wei , LI Li-hua , *et al*
- 2333 The effect of Qingre Lishi Huoxue treatment on bone metabolism and clinical efficacy observation in patients with active rheumatoid arthritis based on OPG/RANKL/RANK signal pathway ZHANG Di , FAN Bing , LIU Ying , *et al*
- 2338 The potential therapeutic value of iguratimod in preclinical rheumatoid arthritis LIU Qun , SHAO Hui-jun , LI Xiao-ling , *et al*
- 2345 A case of treatment with abatacept to rheumatoid arthritis in which multiple biologics failed WU Chun-ye , KAN Yan , KONG Chun-yu
- 2350 Application and governance of real-world data in the field of OTC drugs ZHANG Ying , WANG Wen-ya
- 2355 Comparison of National Medical Products Administration, FDA and ICH guidelines in biowaiver based on biopharmaceutics classification system WANG Gong-fu , TANG Jia , BAI Yu , *et al*
- 2361 The bioequivalence study design and review consideration of aspirin enteric-coated tablets WANG Jing , LI Li , CHEN Si , *et al*
- 2365 Writing of nonclinical research data in common technical document format dossier of pharmaceutical products ZHOU Heng , DAI Xue-dong , ZHAI Yun , *et al*
- 2369 Animal models of choroidal neovascularization in ophthalmic membrane and their correlation with clinical pathogenesis XIE Jin-hua , SONG Shuo , XIONG Ya-ni , *et al*
- 2377 Research progress of radionuclide drug conjugates TAO Qiao-yu , XU Bo-hua , LI Man-qi , *et al*
- 2385 Literature analysis of 33 cases of adverse drug reactions of sintilimab WU Yu-pei , YIN Yue-song , ZHANG Li-na , *et al*

Directed by : National Medical Products Administration
Sponsored by : China Medical Science Press
China National Pharmaceutical Group Corp.
Chinese Pharmaceutical Association
Editor-in-Chief : SANG Guo-wei
Board Chairman : SHI Sheng-yi
Edited by : Editorial Board of Chinese Journal of New Drugs
Published by : Chinese Journal of New Drugs Co., Ltd.
Address : Room 317, No.3 Chengming Building, No.2 Xizhimen South
Street, Xicheng District, Beijing 100035, China
Tel : (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>
E-mail : bianjibu@newdrug.cn
Printer : Beijing Kexin Printing Co., Ltd.
Domestic Distribution : Beijing Post Offices
Overseas Distribution : China International Book Trading Corp.
(P.O.Box 399 Beijing, China)
Domestic Subscription : Local Post Offices
Periodical Registration : ISSN 1003-3734 CN 11-2850/R
Publication Date : December 15, 2022
Copyright : 2022 by Chinese Journal of New Drugs Co.,Ltd.